SCHEMBL2269555

SCHEMBL2269555

O=C(Nc1cc(Oc2cccc(F)c2)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPSE Q9Y251 1/20 0.55
PYGM P11217 3/20 0.55
PYGL P06737 3/20 0.55
TDP1 Q9NUW8 2/20 0.54
MEN1 O00255 2/20 0.54
PKM P14618 2/20 0.54
KMT2A Q03164 2/20 0.54
MAPT P10636 1/20 0.54
GRIK1 P39086 1/20 0.54
SERPINE1 P05121 1/20 0.53
GALK1 P51570 1/20 0.53
CASP6 P55212 1/20 0.53
MCL1 Q07820 1/20 0.53
PLEC Q15149 1/20 0.53
P2RY14 Q15391 1/20 0.53
NPC1 O15118 1/20 0.51
HPGD P15428 1/20 0.51
RAB9A P51151 1/20 0.51
NR1H4 Q96RI1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2274830 0.94 MEN1 (0.54) HPSEPYGMPYGLMEN1PKM
SCHEMBL2271524 0.91 PYGM (0.56) HPSEPYGMPYGLTDP1MEN1
SCHEMBL2274811 0.90 PYGM (0.57) HPSEPYGMPYGLTDP1MEN1
SCHEMBL2271588 0.90 SERPINE1 (0.64) HPSEPYGMPYGLTDP1MEN1
SCHEMBL2291684 0.89 SERPINE1 (0.61) MEN1PKMKMT2ASERPINE1P2RY14
SCHEMBL2273634 0.89 SERPINE1 (0.60) HPSEPYGMPYGLTDP1MEN1
SCHEMBL2292513 0.87 SERPINE1 (0.62) HPSETDP1MEN1PKMKMT2A
SCHEMBL2275435 0.86 PYGM (0.56) HPSEPYGMPYGLTDP1MEN1
SCHEMBL2271920 0.86 SERPINE1 (0.57) HPSEPYGMPYGLTDP1MEN1
SCHEMBL2276447 0.86 SERPINE1 (0.54) HPSEPYGMPYGLTDP1SERPINE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 HPSE 1324/4885PYGM 1299/4885PYGL 1834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.